Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanoquinacrine
- Development stage
- Preclinical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Not Established; Administered In Vivo In Preclinical Mouse Xenograft Models By Injection[1]
01
Overview
**Nanoquinacrine** is a nanoparticle formulation of quinacrine developed to enhance its anti-cancer effects, especially against cervical cancer cells and cancer stem cells. Compared to conventional quinacrine, nanoquinacrine demonstrates increased cytotoxicity and efficacy in preclinical models. Its mechanism of action involves inhibiting the Hedgehog-GLI (HH-GLI) signaling pathway by directly binding to the GLI1 DNA complex, leading to downregulation of tumor-promoting GLI targets, increased expression of negative regulators such as GSK3β and PTEN, and induction of apoptosis in cancer stem cells. This nanoformulation addresses pharmacokinetic limitations of quinacrine, improving drug delivery and tumor targeting[1][4].
- Brand names
- nanoquinacrine
- Other names
- NQCnano-QC
02
Targets
PTEN (Phosphatase and tensin homolog deleted on chromosome ten)GLI1GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on nanoquinacrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanoquinacrine.